Table 3 Baseline biomarker levels and the probability of response to NSI-189 at day 28

From: Erratum: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Patient. ID

Designation

Probablilty

501

PR

1.000

502

R

1.000

504

R

1.000

505

R

1.000

506

R

1.000

508

NR

0.032

602

R

1.000

603

R

0.961

604

PR

1.000

606

PR

0.998

608*

PR*

0.000*

627

R

0.980

701

R

1.000

702

R

0.987

703

NR

0.000

705

NR

0.031

706

R

1.000

707

R

0.995

  1. Abbreviations: A1AT, alpha-1-antitrypsin; BNF, brain-derived neurotrophic factor; EGF, epidermal growth factor; MADRS, montgomery-asberg depression scale; MPO, myeloperoxidase; NR, non-responder; PR, partial responder; R, responder; TNFR2, tumor necrosis factor receptor type 2. Indicates the individual patient identifier, and the response group designation (R, PR and NR) and the predicted probability of response based upon analysis of baseline biomarker data. We used partial least squares discriminant analysis to choose the important variables (BDNF, EGF, MPO, TNFR2 and A1AT) in predicting response. One possible outlier (*) was patient 608 who was designated a partial responder based on a single MADRS score of 16 which indicated a change from moderate to mild depression. The observed probability was consistent with the patient being a NR.
Back to article page